Literature DB >> 2133286

Priming of human monocytes with PAF augments their production of tumor necrosis factor.

M Rola-Pleszczynski1.   

Abstract

We have recently shown that platelet-activating factor (PAF) can markedly enhance the production of tumor necrosis factor (TNF) and interleukin-1 (IL-1) by human monocytes stimulated with lipopolysaccharide or muramyl dipeptide (MDP). Because inflammatory mediators may act sequentially in vivo, we studied the effect of preexposure of monocytes to PAF on their subsequent response to cytokines in terms of TNF production. Priming monocytes for 18-48 h with graded concentrations of PAF (10(-16)-10(-6) M) markedly enhanced their subsequent TNF production in response to MDP and MDP + cytokines, by two- to three-fold. Our data suggest that priming of monocytes by PAF may be an important step in augmenting their subsequent activities in inflammatory or immune responses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2133286

Source DB:  PubMed          Journal:  J Lipid Mediat        ISSN: 0921-8319


  3 in total

Review 1.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

2.  Platelet-activating-factor-mediated pathogenesis in Lyme disease.

Authors:  E Isogai; K Kimura; N Fujii; T Nishikawa; N Ishii; D Postic; G Baranton; H Isogai
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

3.  Inhibition of PAF synthesis by stimulated human polymorphonuclear leucocytes with cloricromene, an inhibitor of phospholipase A2 activation.

Authors:  E Ribaldi; A M Mezzasoma; E Francescangeli; M Prosdocimi; G G Nenci; G Goracci; P Gresele
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.